Technical / White Paper

Why Are MDs Testing Vitamin K2?

Published

Format: PDF file | Document type: Technical / White Paper

NattoPharma

Some MDs believe a vitamin could be a viable therapy for patient populations facing calcification.

The clinical evidence for MenaQ7®​ Vitamin K2 as MK-7, including an intervention study showing significant benefits for cardiovascular health and arterial elasticity, have convinced the traditional medical community to sponsor studies in patient populations prone to calcification. Trials looking at coronary artery calcification, aortic calcification, dialysis, and other patients are now underway.

Learn more about the evidence with MenaQ7®​ in healthy populations that have lead researchers to now examine K2 as a therapy.

Related resources from NattoPharma USA, Inc.

Show more

Supplier info centre